In 2019, the clinical approval study for Transcranial Pulse Stimulation (TPS) with STORZ MEDICAL’s NEUROLITH® system was published in the prestigious journal Advanced Science [1]. Prof. Dr. Beisteiner’s study, which was conducted at the Medical University of Vienna Beisteiner, documents the positive effects of TPS in the treatment of patients with Alzheimer’s dementia.
Une étude publiée en janvier 2022 par Matt et al. (Université de médecine de Vienne, Clinique universitaire de neurologie) examine les effets à long terme sur le cerveau et le comportement humains de la stimulation transcrânienne par impulsions (TPS) à l’aide du système NEUROLITH®1. L’étude randomisée, réalisée en double aveugle et contre placebo, fournit pour la première fois une preuve contrôlée contre placebo des effets associés.
Une nouvelle étude publiée en février 2022 par Matt et al. (Université de médecine de Vienne, Clinique universitaire de neurologie) a présenté une sous-analyse détaillée dans laquelle, sur la base de données neuropsychologiques et d'imagerie fonctionnelle, les effets antidépresseurs possibles de la Stimulation transcrânienne par impulsions (TPS) à l'aide du système NEUROLITH® sont examinés.2
The acoustic pulses generated by Transcranial Pulse Stimulation (TPS) have been used successfully in various medical fields (urology, orthopaedics, cardiology….) for decades under the term »extracorporeal shock wave therapy«.
Shock waves are similar to ultrasound. But there is a major difference:
The authors of a follow-up study (published in 2021) investigated the possible benefits of TPS treatment concerning brain morphology, namely the cortical atrophy characteristic of Alzheimer’s disease [1]. They found a significant correlation between neuropsychological improvement and cortical thickness increase in AD-critical brain areas.
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® is increasingly gaining momentum: Since the CE approval for the »treatment of the central nervous system of patients with Alzheimer’s disease« in 2018, more than 50 NEUROLITH® systems have been installed worldwide. In June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria, and Turkey.
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system is a new therapy option for patients with Alzheimer’s disease that allows targeted stimulation of cerebral regions.
Key-facts:
Note : la publication suivante et le film projeté sont en allemand.
Im Film »Wie hilft Ultraschall gegen Alzheimer« wird spannend unsere Transkranielle Pulsstimulation (TPS) vorgestellt.
Also das moderne Therapieverfahren zur Behandlung von Alzheimer-Demenz durch die Stimulation verschiedener Gehirnregionen.
One of the highlights of the new NEUROLITH® system is its innovative BodyTrack software – a unique tool for the visualization and control of the TPS pulses applied and of treatment progress. Real-time tracking of the handpiece position enables automatic visualization of the treated regions. The use of personalized MRI data allows specific characteristics of the patient’s brain to be taken into account.
»Overall, I feel good after the treatment and progress has been made. I notice that I respond well when someone talks to me and find the words to express myself better. In addition, my memory has improved somewhat. When I go shopping, I take the shopping list just to be on the safe side, although I could do without it.
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system is performed by a trained practitioner and is done on an outpatient basis. During treatment, the patient sits comfortably in a chair and can move freely at any time. To ensure optimal transmission of the pulses, the therapist applies ultrasound gel to the scalp or hair – it is not necessary to shave the patient’s head. The patient then puts on a pair of special glasses so that the position of the head can be detected.
